Incyte Corp ( INCY) as of Mon, Dec 11, 2017

Sections on this page: Stock Price | Stock Charts | Company Profile | Earnings

INCY Stock Price Today $97.25

 The recent INCY stock price today is $97.25 +0.67 (0.69%) for Mon, Dec 11, 2017.

Year To Date

The Year To Date (YTD) return is -4.96%.

52 Week Low

The 52 Week Low stock price is 92.91 set on Wed, Dec 6, 2017 which is 6 days ago.

The current price per share is 4.67% above the 52 week low.

52 Week High

The 52 Week High stock price is $153.15 set on Wed, Mar 15, 2017 which is 272 days ago.

The current price per share is -36.50% below the 52 week high.

All Time High

The All Time High stock price is $153.15 set on Wed, Mar 15, 2017 which is 272 days ago.

The current price per share is -36.50% below the all time high.

Incyte Stock Charts

The 5 year and 1 year stock charts are below.

5 Year Stock Chart

The Incyte 5 year stock chart shows the historical prices over the previous 60 months.

Incyte 5 year stock chart

1 Year Stock Chart

The Incyte 1 year stock chart shows the historical prices over the previous 12 months.

Incyte 1 year stock chart

50 Day Moving Average

The 50 Day Moving Average is at $129.58 which is 24.95% above the stock price of $97.25.

200 Day Moving Average

The 200 Day Moving Average is at 124.16 which is 21.67% above the stock price of $97.25.

INCY Company Profile

Incyte Corp LogoIncyte Corp is a Health Care stock that trades on the NASDAQ and has a market capitalization of $20.38 Billion.

http://www.incyte.comIncyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

For more information and analysis about Incyte Corp, visit their web site at http://www.incyte.com. For a real time price lookup on this ticker, INCY, visit Google Finance and Bloomberg.

Below are several other Biotech & Pharma stocks include AbbVie Inc (ABBV), Allergan PLC (AGN), Alexion Pharmaceuticals Inc (ALXN), Amgen Inc (AMGN), Biogen Inc (BIIB), BioMarin Pharmaceutical Inc (BMRN), Bristol-Myers Squibb Co (BMY), Celgene Corp (CELG), Endo International PLC (ENDP), Gilead Sciences Inc (GILD), .

INCY Earnings

 Below is the EPS, P/E Ratio and Earnings Date.

Earnings Per Share

The EPS is -$0.8 and the P/E Ratio is 0.

Earnings Dates

The Earnings Release Date was Tue, Aug 1, 2017.

Since this earnings release 133 days ago, the stock price is down by -27.04%.

The most recent Earnings Release Date was on Tue, Oct 31, 2017, which was 42 days ago.

Since this earnings date, the stock price is down by -14.87%.

Incyte Dividend

INCY currently does not pay a dividend.